We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Donated Blood Could Be Transformed Into Universal Type

By LabMedica International staff writers
Posted on 10 May 2015
Blood transfusions are critically important in many medical procedures, but the presence of antigens on erythrocytes means that careful blood-typing must be carried out prior to transfusion to avoid adverse and sometimes fatal reactions following transfusion.

Every day, thousands of people need donated blood, but only blood without A- or B-type antigens, such as type O, can be given to all of those in need, and it's usually in short supply. More...
However an efficient way to transform A and B blood into a neutral type that can be given to any patient has been reported.

Scientists at the University of British Columbia (Vancouver, BC, Canada) working with other Canadian and French investigators studied how to enzymatically remove the terminal N-acetylgalactosamine or galactose of A- or B-antigens, respectively, which would yield universal O-type blood. They started with the family 98 glycoside hydrolase from Streptococcus pneumoniae SP3-BS71 which cleaves the entire terminal trisaccharide antigenic determinants of both A- and B-antigens from some of the linkages on red blood cell surface glycans. Through several rounds of evolution, they developed variants with vastly improved activity toward some of the linkages that are resistant to cleavage by the wild-type enzyme.

The investigators fine-tuned one of those enzymes and improved its ability to remove type-determining sugars by 170-fold, rendering it antigen-neutral and more likely to be accepted by patients regardless of their blood type. The authors concluded that the resulting enzyme effects more complete removal of blood group antigens from cell surfaces, demonstrating the potential for engineering enzymes to generate antigen-null blood from donors of various types. In addition to blood transfusions, the scientists say their advance could potentially allow organ and tissue transplants from donors that would otherwise be mismatched. The study was published on April 14, 2015, in the Journal of the American Chemical Society.

Related Links:

University of British Columbia 



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.